Last Price$318.9(2.6%)
Market Cap$173.1B
18.6%
Peers median - 6.4%
31.1%
Peers median - 22.2%
1,022.6%
Peers median - 72.8%
11.9%
Peers median - 16.7%
Competing with AMGN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$173.1B | 5.9 | $447.8 40.4% undervalued | 19.3% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$743.9B | 7.0 | $225.3 72.7% overvalued | 12.9% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$398.7B | 5.9 | $197.1 18.9% undervalued | 6.2% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$375.8B | 6.0 | $302.4 41.6% undervalued | 23.2% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$346.3B | 7.1 | $72.1 7.7% overvalued | (40.0%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$240.8B | 7.5 | $112.5 18.8% undervalued | (20.7%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$232.5B | 6.7 | $69.5 6.3% overvalued | 11.9% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$223.3B | 6.6 | $149.6 34.3% undervalued | 9.8% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$148.1B | 6.0 | $25.3 2.7% overvalued | (2.7%) | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$146.8B | 4.7 | $91.4 55.6% undervalued | 25.2% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$143.2B | 6.1 | $91.1 20.4% overvalued | 58.1% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
Compare AMGN Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Amgen Inc.AMGN
6.6x
18.6%
(39.8%)
12.2%
Median Peer Set
4.7x
7.8%
11.0%
14.4%
AbbVie Inc.ABBV
7.8x
3.7%
(11.4%)
7.6%
AstraZeneca PLCAZN
4.8x
18.0%
18.9%
13.0%
Gilead Sciences, Inc.GILD
5.5x
6.0%
(91.6%)
1.7%
Johnson & JohnsonJNJ
4.6x
4.3%
(57.9%)
15.8%
Eli Lilly and CompanyLLY
17.2x
32.0%
102.4%
23.5%
Merck & Co., Inc.MRK
4.1x
6.7%
4,714.3%
26.7%
Novo Nordisk A/SNVO
8.4x
24.9%
142.8%
34.8%
Novartis AGNVS
4.7x
10.8%
(16.5%)
23.1%
Pfizer Inc.PFE
3.0x
8.8%
273.7%
12.6%
SanofiSNY
3.3x
(3.8%)
3.1%
12.6%
Compare AMGN Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Amgen Inc. (AMGN) revenue growth compare to peers and the industry?
Amgen Inc. (AMGN) revenue growth is 18.6%, compared to the peers' median of 6.4%.
2. How does Amgen Inc. (AMGN) Free Cash Flow (FCF) margin compare to peers and the industry?
Amgen Inc. (AMGN) FCF margin is 31.1%, compared to the peers' median of 22.2%.
3. How does Amgen Inc. (AMGN) Total Debt to Equity ratio compare to peers and the industry?
Amgen Inc. (AMGN) Total Debt to Equity ratio is 1,022.6%, compared to the peers' median of 72.8%.
4. How does Amgen Inc. (AMGN) ROIC (Return on Invested Capital) compare to peers and the industry?
Amgen Inc. (AMGN) ROIC is 11.9%, compared to the peers' median of 16.7%.